Opportunistic infections update. See p. 14. FDA rejects nitazoxanide, approves TB and hepatitis treatments. Diarrhea drug rejection raises a ruckus. Advisory Committee votes against approval.
Opportunistic infections update.
See p. 18. Nitazoxanide for cryptosporidial diarrhea. Thalidomide shows benefit for microsporidial diarrhea. Furazolidone shows benefits for microsporidial diarrhea. Nitazoxanide shows efficacy for cryptosporidial diarrhea.